中文

ImmunityBio (IBRX)

Healthcare

Close on Nov 9, 2026 (from our latest article): $7.11

Market value
$7.6Bat the Nov 9 close
Revenue growth
+121%12 months to Sep 30, 2026 (10-Q)
FCF margin
−163%12 months to Sep 30, 2026 (10-Q)
Net debt
$927Mat Sep 30, 2026
Worst fall since listing
−97.1%Jul 29, 2015 to Jun 10, 2019; back to that high in Feb 2021

About the company

Latest

  • Down 17.7% Move
    ImmunityBio falls 18% as Anktiva sales slip, overshadowing a trial win

The Long View

What the filings say about the story, dilution and cash runway.

No Long View yet. Request one →

Our View Opinion

Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.

No Our View yet. Request one →

Long-term fundamentals

Annual results for ImmunityBio, FY2013–FY2025, as reported in its 10-K filings.

Revenue and free cash flow

Revenue went from $0.6M in FY2013 to $113M in FY2025. Free cash flow was positive in 0 of the 13 years shown; FY2025: −$309M. Each year's figures are in the table below. −$600M−$400M−$200M$0$200M ’13 ’15 ’17 ’19 ’21 ’23 ’25

Revenue went from $0.6M in FY2013 to $113M in FY2025.

Free cash flow was positive in 0 of the 13 years shown; FY2025: −$309M.

Margins

Margins are not charted: in FY2025 the operating loss (−$256M) was larger than revenue ($113M). The table has each year's figures.

Diluted share count

The diluted share count rose 144% from FY2020 to FY2025, to 920M. Each year's figures are in the table below. 200M400M600M800M1B ’19’20’21’22’23’24’25

The diluted share count rose 144% from FY2020 to FY2025, to 920M.

Results and cash flow

Fiscal yearRevenueGross marginOperating marginNet incomeOperating cash flowCapital spendingFree cash flow
FY2025$113M—−226%−$351M−$305M$4M−$309M
FY2024$15M—−2334%−$414M−$391M$7M−$398M
FY2023$0.6M—−58240%−$583M−$367M$31M−$397M
FY2022$0.2M—−146374%−$417M−$338M$78M−$416M
FY2021$0.9M—−35362%−$347M−$274M$34M−$308M
FY2020$0.6M—−36509%−$222M−$172M$2M−$173M
FY2019$2M—−7096%−$158M−$152M$4M−$156M
FY2018$0.0M—−209338%−$96M−$63M$13M−$76M
FY2017$0.0M—−220267%−$96M−$49M$35M−$84M
FY2016$0.0M—−282955%−$121M−$39M$7M−$45M
FY2015$0.2M—−101219%−$237M−$25M$2M−$28M
FY2014$0.6M—−870%−$6M−$5M$0.2M−$6M
FY2013$0.6M——−$2M−$0.7M$0.0M−$0.7M

Shares, cash, debt and payouts

Fiscal yearDiluted sharesCash and investmentsDebtStock-based payDividends paidBuybacks
FY2025920M$243M$325M$37M——
FY2024700M$150M$284M$34M——
FY2023509M$266M$577M$49M——
FY2022400M$107M$673M$40M——
FY2021389M$317M—$57M—$0
FY2020377M$96M—$2M—$0
FY2019366M$113M—$3M—$3M
FY2018—$80M—$23M—$0.2M
FY2017—$158M—$37M—$15M
FY2016—$199M—$74M—$16M
FY2015—$294M—$211M—$5M
FY2014—$59M—$0.8M—$0
FY2013—$0.3M—$0.9M——

Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 9, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.

  • Free cash flow here does not subtract principal payments on finance leases (FY2025: $0M); a company measure that does will be lower by that amount.

Returns by year

YearIBRXS&P 500
2019+226.7%+31.5%
2020+251.7%+18.4%
2021−54.4%+28.7%
2022−16.6%−18.1%
2023−1.0%+26.3%
2024−49.0%+25.0%
2025−22.7%+17.9%
2026 to date+231.8%+5.9%

Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.

Other companies we cover in Healthcare

Questions about ImmunityBio

Why did ImmunityBio stock fall on Nov 9, 2026?
ImmunityBio's sales of Anktiva, its bladder-cancer drug, fell from the second quarter for the first time since its launch, and total revenue of $48.8 million missed the $59.2 million estimate from Fiscal.ai, cited by Stocktwits. The same morning it said a registrational trial in newly diagnosed patients met its main goal, but it gave no response rates. The shares closed down about 18% on a day biotech stocks rose, after rising about 336% from the end of 2025 through Friday (Yahoo Finance closes; our calculation). Read the article →